MEK inhibitors have shown potential in thyroid cancer treatment by enhancing iodine uptake and retention, inducing G0/G1 cell cycle arrest through reduced MEK/ERK phosphorylation, and inhibiting the viability of cells harboring BRAF mutations. Here, MAP2K7 is linked to thyroid cancer.